Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives
Open Access
- 13 February 2021
- Vol. 9 (2), 151
- https://doi.org/10.3390/vaccines9020151
Abstract
Respiratorytract infections (RTIs) are frequent and life-threatening diseases, accounting for several millions of deaths worldwide. RTIs implicate microorganisms, including viruses (influenza virus, coronavirus, respiratory syncytial virus (RSV)), bacteria (Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus and Bacillus anthracis) and fungi (Pneumocystis spp., Aspergillus spp. and very occasionally Candida spp.). The emergence of new pathogens, like the coronavirus SARS-CoV-2, and the substantial increase in drug resistance have highlighted the critical necessity to develop novel anti-infective molecules. In this context, antibodies (Abs) are becoming increasingly important in respiratory medicine and may fulfill the unmet medical needs of RTIs. However, development of Abs for treating infectious diseases is less advanced than for cancer and inflammatory diseases. Currently, only three Abs have been marketed for RTIs, namely, against pulmonary anthrax and RSV infection, while several clinical and preclinical studies are in progress. This article gives an overview of the advances in the use of Abs for the treatment of RTIs, based on the analysis of clinical studies in this field. It describes the Ab structure, function and pharmacokinetics, and discusses the opportunities offered by the various Ab formats, Ab engineering and co-treatment strategies. Including the most recent literature, it finally highlights the strengths, weaknesses and likely future trends of a novel anti-RTI Ab armamentarium.Funding Information
- MAbImprove (ANR-10-LABX -53-01)
This publication has 75 references indexed in Scilit:
- Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and ChildrenAntimicrobial Agents and Chemotherapy, 2012
- Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivoMolecular Microbiology, 2011
- The Remaining Challenge of PneumoniaThe Pediatric Infectious Disease Journal, 2011
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoireProceedings of the National Academy of Sciences of the United States of America, 2009
- Pathophysiology of anthraxFrontiers in Bioscience-Landmark, 2009
- Role of polysaccharides in Pseudomonas aeruginosa biofilm developmentCurrent Opinion in Microbiology, 2007
- Diagnosis and Management of BronchiolitisPEDIATRICS, 2006
- By-passing immunization: Human antibodies from V-gene libraries displayed on phageJournal of Molecular Biology, 1991
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975